Last update April 18, 2022


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Steroid drug for topical use in skin, eye and external ear.

DERMATOLOGICAL USE: Because of a low absorption through skin significant excretion into breast milk is unlikely. Additionally, its high volume of distribution makes its excretion in breast milk difficult.

Whenever a treatment for nipple eczema or dermatitis is required the lowest potency steroid compound (hydrocortisone, triamcinolone) should be used. It should be applied right after the feed to make sure it has disappeared before the next nursing occurs. Otherwise, wipe cream out with a clean gauze.

Do not continuously use for longer than a week.

Reportedly, a case of mineral-steroid toxicity has occurred due to continuous use of cream on the nipple. Creams, gels or similar products that contain paraffin or mineral oil should not be used on the nipple to avoid absorption by the infant. (De Stefano 1983)


The small dose used and a sparse absorption into the plasma of topical treatments for ophthalmologic conditions make excretion into breast milk in significant amount unlikely. In order to minimize even more the tiny amount excreted in the milk, press the lacrimal duct for 1-2 minutes after instillation of fluid and dry out the excess of it with a paper tissue.

List of WHO essential medicines: compatible with breastfeeding. (WHO-UNICEF 2002)

See below the information of this related product:

  • Dexamethasone (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


地塞米松 belongs to this group or family:


Main tradenames from several countries containing 地塞米松 in its composition:

  • De-Phonal™. Contains other elements than 地塞米松 in its composition
  • Oftalmolosa Cusi de Icol™. Contains other elements than 地塞米松 in its composition
  • Otocort™. Contains other elements than 地塞米松 in its composition
  • Phonal™. Contains other elements than 地塞米松 in its composition
  • Resorborina™. Contains other elements than 地塞米松 in its composition


Variable Value Unit
Oral Bioavail. 78 %
Molecular weight 392 daltons
Protein Binding 70 %
VD 0.7 - 1.3 l/Kg
pKa 12.4 -
Tmax 1 - 2 hours
3 - 6 hours


  1. PDR.NET Ophtalmic Dexamethasone Drug Summary 2014 Full text (link to original source) Full text (in our servers)
  2. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  3. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM